



GLOBAL JOURNAL OF MEDICAL RESEARCH: F
DISEASES

Volume 19 Issue 2 Version 1.0 Year 2019

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Bohring-Opitz Syndrome: First Latinoamerican Case and Review of the Literature

By Daniela Alejandra Tolosa Quintero, Carolina Rivera Nieto
& Juan Sebastián Leguizamón Melo

University of Rosario

Introduction- The Bohring-Opitz syndrome (BOPS) was first described in 1999 by Bohring et al (1). It is an extremely rare genetic condition, of unknown prevalence, which is caused by de novo or nonsense mutations in the ASXL1 gene. To date 46 people with BOPS have been described, of whom only 20 have a confirmed molecular diagnosis. The BOPS diagnosis is established by clinical suspicion and / or identification of a constitutional heterozygous pathogenic variant in the ASXL1 gene (2). This article shows the first case in Latin America of BOPS confirmed by molecular diagnosis.

Keywords: *Bohring Opitz Syndrome, ASXL1, HOX genes, BOPS.*

GJMR-F Classification: *NLMC Code: QU 450*



Strictly as per the compliance and regulations of:



© 2019. Daniela Alejandra Tolosa Quintero, Carolina Rivera Nieto & Juan Sebastián Leguizamón Melo. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License <http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bohring-Opitz Syndrome: First Latinoamerican Case and Review of the Literature

Daniela Alejandra Tolosa Quintero ^α, Carolina Rivera Nieto ^σ & Juan Sebastián Leguizamón Melo ^ρ

Keywords: *Bohring Opitz Syndrome, ASXL1, HOX genes, BOPS*

I. INTRODUCTION

The Bohrning-Opitz syndrome (BOPS) was first described in 1999 by Bohring et al (1). It is an extremely rare genetic condition, of unknown prevalence, which is caused by de novo or nonsense mutations in the ASXL1 gene. To date 46 people with BOPS have been described, of whom only 20 have a confirmed molecular diagnosis. The BOPS diagnosis is established by clinical suspicion and / or identification of a constitutional heterozygous pathogenic variant in the ASXL1 gene (2). This article shows the first case in Latin America of BOPS confirmed by molecular diagnosis.

II. CASE REPORT

We present an 8-year-old male patient, born to term at 38 weeks, presented intrauterine growth restriction with birth weight of 2200 grams (P 0.4, Z -3.1) and a birth length of 48 centimeters (P 17, Z 0.95). He was hospitalized for 40 days in the neonatal intensive care unit (NICU) where he received mechanical ventilation for the first six days. During his hospital stay in NICU an echocardiogram was performed and a moderate mitral regurgitation, a moderate pulmonary hypertension and an ostium secundum interatrial communication were identified. No evidence of hemodynamic repercussion was found. At one year of age a ventricular dilatation are evidenced in brain MRI. Developmental delay was documented. Physical exam showed discrete synophris, ocular hypertelorism, myopia, bilateral sensorineural hearing loss, cleft palate, velo-palatal incoordination, cryptorchidism, left thoracolumbar scoliosis, pre-axial polydactyly in the hands and hypotonia. Current anthropometry was: weight 25 kg (P21, Z -0.8) and height 120 cm (P2, Z -2.1), IMC 17.4 (P75, Z 0.67)

In the first year of life, severe uptake-swallowing disorder managed with gastrostomy is documented; later, in the preschool age he presented

multiple hospitalizations due to infectious diseases, pneumonias and recurrent otitis, because of this, immunodeficiency was ruled out. He developed symptomatic refractory epilepsy that was treated with carbamazepine and topiramate. Finally, Bohrning-Opitz syndrome was suspected [25], a complete sequencing of the ASXL1 gene was performed, identifying the heterozygous variant C.2893C>T (p.Arg965*) that confirmed the diagnosis of BOPS.

III. DISCUSSION

The Bohrning-Opitz Syndrome (BOS, OMIM 605039) is caused by de novo or nonsense mutations in the ASXL1 gene (OMIM 612990) (3), that accounts for about 50% of the cases that meet the clinical criteria. The gene locus is located on chromosome 20q11.21, contains 13 exons and codes for the sex-combs-like 1 protein, which is a polypeptide of 1543 amino acids (2, 4). The sex-combs-like 1 protein is involved in the remodeling of chromatin in localized areas and helps to activate and silence the transcription of different genes involved in the regulation of the expression of HOX genes, involved in embryonic development for determination of the basic structure and orientation of the embryo (5), which proposes a mechanism of loss of function, that is, haploinsufficiency, as the fundamental cause of the BOPS clinical picture. (3)

To date, genotype-phenotype correlations have not been reported because of the few number of individuals in whom pathogenic variants in the ASXL1 gene have been identified (2). The described phenotype of the BOPS includes distinctive facial and postural features, delayed neurodevelopment, failure of thrive and other associated clinical conditions of variable presentation. Table 1 summarizes the most representative clinical characteristics.

Author α: Medical Resident of pediatrics, Master of Education. University of Rosario. Bogota Colombia. e-mail: daleja2012@gmail.com

Author σ: Medical Geneticist. Chief of Medical Genetics. Cardioinfantil Foundation. Bogota Colombia. e-mail: carolinariveran@gmail.com

Author ρ: Resident doctor of pediatrics, University Foundation of Health Sciences. Bogota Colombia. e-mail: juancho1309@gmail.com



Table 1: Summary of BOPS clinical characteristics the adapted from Russell et al.

Skull	Microcephaly Or Trigenocephaly And Prominent Metopic Crest.
Face	<i>Nevus flammeus</i> that fades with age, telecanthus, hypoplastic supraorbital crests, ptosis, strabismus, glaucoma, hypertrichosis, anteverted nostrils, cleft lip, cleft palate, arched palate or prominent palatine ridges and micrognathia / retrognathia.
Central Nervous System	Ventriculomegaly, delayed myelination, delayed neurodevelopment, severe or profound intellectual disability, Dandy-Walker malformation and seizures.
Osteomuscular	congenital dislocations.
Gastrointestinal	Functional constipation, chronic emesis and gastroesophageal reflux.
Cardiovascular	Defects of the atrial septum, persistent ductus arteriosus, valvular anomalies and pulmonary stenosis.
Respiratory	Repeated broncho-obstructive episodes and obstructive sleep apnea
Hematological	Acute myeloid leukemia, sideroblastic anemia, Wilms tumor and myelodysplastic syndromes.
Immunological	Upper respiratory tract repeated infections
Typical Posture	Elbow, wrists and flexed metacarpophalangeal joints, ulnar deviation, of the hands and hypertonic limbs with central hypotonia.

The facial features are distinctive and include pronounced microcephaly in the early years of childhood, trigonocephaly that is generated from the prominence of the metopic ridge and a narrowing at the bitemporal level (6), hypotonic facies, "nevus flammeus", telecantho, hypoplastic supraorbital crests, upward

slanting palpebral fissures, depressed nasal bridge, anteverted nostrils, hairy and arched eyebrows, posteriorly rotated ears, hypertrichosis, micrognathia and narrow and high palate (see figure 1) (7). Facial manifestations tend to become less noticeable with age. (8)



Figure 1: Facial lesion type "Nevus flammeus", telecanthus, thick arched eyebrows, hypoplastic supraorbital ridges, depressed nasal bridge, anteverted nostrils and hypertelorism are observed

At the ocular level, ptosis, strabismus that does not resolve, and glaucoma due to pressure increase at the level of the anterior chamber of the eye are evident. (7) Similarly, alterations of the retina and the optic nerve, which include colobomas, optic nerve atrophy, atrophy of the retina and / or abnormal pigmentation that explain visual impairment (2, 9) are common. Patients diagnosed with BOPS who have a mutation identified in the ASXL1 gene have a higher incidence of myopia (87% versus 40%) and

hypertrichosis (89% versus 17%), compared to those without mutations. (5)

A typical BOPS posture that is commonly identified in early childhood and becomes less apparent with age has been described: it presents with shoulders directed towards the midline, extremities flexed distally (elbows, wrists and fingers) forming a fixed contracture position (see figure 2) (6). Despite the typical posture, no studies have been found that relate it to CNS alterations, muscle tone or joint dislocations (1).



Figure 2: Typical posture, elbows, wrists and metacarpophalangeal joints in fixed forward contracture. At the abdominal level, a gastrostomy button is evident.



Figure 3: Ortho-radiography at 7 years of age, showing a scoliotic left lumbar curve with a scoliosis angle of 46° and a right dorsal compensatory curvature with a scoliosis angle of 34° . On the lateral side there is an increase in the dorsal kyphosis at an angle of 63° .

In addition, alterations in muscle tone ranging from flaccidity to hypotonia of the upper and lower extremities leading to alterations in the curvatures of the spine are described (Figure 3) (6). Similarly, congenital contractures, dislocations and pectus excavatum are observed (2); the congenital dislocation of the hip and

the radial head are reported in up to 33% of the cases, the first was evidenced in the present patient (Figure 4).



Figure 4: Congenital dislocation of ankles that hinders independent sitting and bipedestation.

In the central nervous system, ventriculomegaly, delayed myelination, Dandy-Walker malformation and generalized atrophy with abnormalities in neuronal migration that favors the development of seizures have been identified (4). These findings may explain the variable intellectual disability, the deficit of language and the difficulties for independent bipedestation. Very few achieve an independent walking.(6) It is described that children with BOPS can recognize caregivers and have a social and interactive nature, so they are seen with a happy and pleasant attitude.

Patients with BOPS have swallowing difficulties since early childhood, functional constipation, gastroesophageal reflux (GER), cyclical vomiting and poor suction; which are related to poor weight gain and are thought to be have a neurogenic origin (10). Gastrointestinal disorders are observed from the first months of life and tend to improve with age. Nevertheless, 53% of the patients require parenteral nutrition or gastrostomy as a definitive form of nutrition (Figure 2), and have a risk of aspiration and dehydration.

Half of patients may have minor cardiac anomalies, transient bradycardia and apnea (2). Similarly, septal and cardiac hypertrophy, persistent ductus arteriosus and valvular anomalies, pulmonary stenosis being the most representative (6). Other findings at the pulmonary level are recurrent broncho-obstructive symptoms and obstructive sleep apnea syndrome (8); the latter improves with the use of CPAP or mandibular traction. People affected with micrognathia may also present airway obstruction based on glossoptosis of the tongue (10).

Patients with BOPS have an inadequate innate and adaptive immune response and are more predisposed to upper respiratory tract infections, pneumonia and acute otitis media. (1) The literature also reports cases of recurrent urinary infections, urinary retention and increased risk of kidney stones (2).

Somatic mutations related to the ASXL1 gene have been associated with acute myeloid leukemia and appear to affect approximately 7% of people with myelodysplastic syndrome; they also present in sideroblastic anemia and Wilms tumor (2, 10). A systematic review demonstrated the relationship between a somatic mutation of the ASXL1 gene and the risk of developing hematological cancers, including chronic myelomonocytic leukemia (up to 43% of cases), myelodysplastic syndrome (20%), myelo- proliferative neoplasms (10%) and acute myeloid leukemia (20%) (11).

If a diagnosis of BOPS is suspected, a sequencing of exons 12 and 13 of the ASXL1 gene, must be performed. (5). In the absence of a mutation identified in these exons of the ASXL1 gene, a somatic mosaicism or genetic heterogeneity is possible (other causal genes not identified to date) (2, 12).

The BOPS prognosis is poor, with a high incidence of childhood mortality (2). Respiratory infections and recurrent wheezing episodes are common and represent 42% of deaths in the first two years of life (10). Death due to cardiovascular causes is associated with bradycardia and apnea, which represent four (33%) of the 12 deaths published in the literature (although none of these individuals had a molecular confirmation of BOPS) (2).

The treatment is symptomatic and focuses on clinical manifestations, cyclic vomiting can be controlled by identifying and avoiding the triggering factors (2). An earlyan enteral route such a gastrostomy has been proposed to reduce bronchoaspiration, improve nutrition and avoid unnecessary hospitalizations (10). Tracheostomy is recommended for patients with recurrent bronchoaspiration who develop secondary lung disease and those with severe sleep apnea who do not improve with non-invasive treatment (CPAP, BiPAP) or with surgery (for example, mandibular distraction) (2).

If a sleep disturbance is present, polysomnography is indicated in order to identify early obstructive apnea (10). The referral to a craniofacial team should be considered for children with palatal anomalies, with micrognathia or with obstructive sleep apnea. Similarly, renal ultrasonography should be performed every three months from birth to eight years to detect the development of a Wilms tumor (2).

Given the rarity of BOPS and the diversity of the phenotype, the clinical suspicion and diagnosis is a real challenge. The awareness of BOPS is needed to describe its natural history and develop tools to establish an early diagnosis and clinical management that could improve the quality of life of these patients.

Ethical Responsibilities

The authors declare that they have followed the protocols of their work center on the publication of patient data and the patient family has given informed consent to it.

Conflict of Interests

The authors declare no conflict of interests.

BIBLIOGRAPHY

- Hastings R, Cobben J, Gillessen-kaesbach G, Goodship J, Hove H, Kjaergaard S, et al. Bohring – Opitz (Oberklaid – Danks) syndrome : clinical study, review of the literature , and discussion of possible pathogenesis. 2011; (September 2010): 513–9.
- Russell B, Tan W-H, Graham J M. Bohring-Opitz Syndrome [Internet]. GeneReviews®. 2018 [cited 2018 Apr 14]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29446906>
- Hoischen A, van Bon BWM, Rodríguez-Santiago B, Gilissen C, Vissers LELM, de Vries P, et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet [Internet]. 2011 Aug 26 [cited 2018 Apr 15]; 43(8): 729–31. Available from: <http://www.nature.com/articles/ng.868>
- Dangiolo S B, Wilson A, Jobanputra V, Anyane-yeboa K. Bohring – Opitz Syndrome (BOS) with a New ASXL1 Pathogenic Variant : Review of the Most Prevalent Molecular and Phenotypic Features of the Syndrome. 2015.
- Magini P, Monica M Della, Luisa M, Uzielli G, Mongelli P, Scarselli G, et al. Two Novel Patients With Bohring – Opitz Syndrome Caused by De Novo ASXL1 Mutations. 2012.
- Gillessen-kaesbach G. Bohring – Opitz (Oberklaid – Danks) syndrome : Clinical study, review of the literature , and discussion of possible pathogenesis. 2014.
- Oudesluijs G, Grange DK, Bohring A, Zampino G, Thierry P. New Cases of Bohring – Opitz Syndrome, Update, and Critical Review of the Literature. 2006; 1263: 1257–63.
- Kleefstra T, Schenck A, Kramer J M, Bokhoven H Van. Neuropharmacology The genetics of cognitive epigenetics. Neuropharmacology. Elsevier Ltd; 2014; 80: 83–94.
- Simpson ARH, Gibbon CEA, Quinn A G, Turnpenny P D. Infantile high myopia in Bohring-Opitz syndrome. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2007 Oct; 11(5): 524–5.
- Russell B, Johnston J J, Biesecker L G, Kramer N, Pickart A, Rhead W, et al. Clinical Management of Patients with ASXL1 Mutations and Bohring – Opitz Syndrome , Emphasizing the Need for Wilms Tumor Surveillance. 2015; (April): 2122–31.
- Sheng M-Y, Zhou Y, Xu M-J, Yang F-C. [Role of ASXL1 mutation in myeloid malignancies]. Zhongguo shi yan xue ye xue za zhi [Internet]. 2014 Aug 22 (4): 1183–7.
- Carlston C M, O'Donnell-Luria A H, Underhill H R, Cummings B B, Weisburd B, Minikel E V, et al. Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome. Hum Mutat 2017 May 38 (5): 517–23.